United Arab Emirates Tuberculosis Testing Market Size & Outlook, 2025-2033
United Arab Emirates Tuberculosis Testing Market Insights
- According to Reed Intelligence analysis, the United Arab Emirates Tuberculosis Testing Market size was USD 85.12 Million in 2024 and is projected to reach USD 141.85 Million by 2033.
- The United Arab Emirates market is projected to grow at a CAGR of 5.81% between 2026 and 2033.
- By segment, Radiographic Test emerged as the largest By Diagnostic Test Type in terms of market size in 2024.
- Radiographic Test is anticipated to remain the most attractive By Diagnostic Test Type segment, recording the fastest growth during the forecast period.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- As of 2024, United Arab Emirates held 4.34% of the global Tuberculosis Testing Market size.
- By 2033, United States is anticipated to capture the largest share of the global Tuberculosis Testing Market.
- In Middle East and Africa, United Arab Emirates is expected to lead the regional Tuberculosis Testing Market size by 2033.
- Turkey will remain the fastest-growing market in Middle East and Africa, reaching USD 28.55 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 85.12 Million |
| Market Size In 2033 | USD 141.85 Million |
| Largest segment | Radiographic Test |
| Units | Revenue in USD Million |
| CAGR | 5.81% (2025-2033) |
| Segmnetation Covered | |
| By Diagnostic Test Type |
|
| By End User |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
United Arab Emirates Tuberculosis Testing Market By Diagnostic Test Type 2025-2033 (USD Million)
| By Diagnostic Test Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Radiographic Test | XX.x | XX.x | XX.x | 24.96 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Smear Microscopy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Culture-Based Test | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Nucleic Acid Test | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Cytokine Detection Test | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Drug Resistance Test | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Other Diagnostic Test Types | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
United Arab Emirates Tuberculosis Testing Market By End User 2025-2033 (USD Million)
| By End User | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital/Clinic | XX.x | XX.x | XX.x | 54.79 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Diagnostics/Research | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
